Gracell IND Application for Phase 1b/2 for Relapsed/Refractory Multiple Myeloma OKd

 BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies

Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023

https://www.biospace.com/article/releases/gracell-biotechnologies-announces-fda-clearance-of-the-ind-application-for-phase-1b-2-clinical-trial-of-fastcar-t-gc012f-for-the-treatment-of-relapsed-refractory-multiple-myeloma/